Axsome Therapeutics Signals Strong Growth in Earnings Call

Axsome Therapeutics Inc. ((AXSM)) has held its Q4 earnings call. Read on for the main highlights of the call.

Axsome Therapeutics’ latest earnings call struck an upbeat tone, with management emphasizing strong revenue growth, accelerating prescription trends, and a rapidly advancing pipeline. While rising expenses and gross‑to‑net pressures weighed on reported profitability, executives framed these as necessary investments to capture what they see as a multi‑year growth opportunity across depression, sleep disorders, and neuropsychiatric indications.

Broad-Based Surge in Revenue

Axsome reported Q4 2025 product revenue of $196 million, a 65% jump versus last year, underscoring strong demand across its portfolio. Full‑year 2025 revenue climbed 66% to $638.5 million, signaling that the company is quickly scaling from a single‑product story into a diversified commercial platform, even as profitability is still a work in progress.

Auvelity Emerges as a Blockbuster Franchise

Auvelity was the star performer, delivering Q4 net sales of $155.1 million, up 68% year over year, and $507.1 million for 2025, an impressive 74% annual increase. Prescriptions exceeded 225,000 in the quarter, with more than 52,000 unique prescribers since launch, positioning Auvelity as a potential blockbuster in major depressive disorder and the key economic engine for Axsome.

Sunosi Delivers Steady Growth

Sunosi continued to build momentum with Q4 net product revenue of $36.7 million, up 40% from a year ago, and $124.8 million for the full year, a 32% increase. Over 54,000 prescriptions were written in the quarter and roughly 15,100 prescribers have used the drug, supporting management’s view that Sunosi can be leveraged into additional indications and patient populations.

Cymbravo Shows Early Traction but Modest Scale

Cymbravo, in only its second full quarter on the market, posted Q4 net sales of $4.1 million and $6.6 million for the year, reflecting an early but small contribution. The drug generated more than 13,000 prescriptions and about 5,300 new patient starts in the quarter, and Axsome has now contracted with a third major GPO, laying groundwork for broader payer negotiations.

Pipeline and Regulatory Milestones Accelerate

On the R&D front, the sNDA for Auvelity in Alzheimer’s disease agitation has been accepted with Priority Review, with a key decision date set for late April 2026 and launch planning already in motion. Management also highlighted an imminent NDA for AXS‑12 in narcolepsy, Phase III initiation for AXS‑05 in smoking cessation this quarter, and multiple Phase III programs for solriamfetol and AXS‑14 in fibromyalgia, reinforcing Axsome’s ambitions beyond its current labels.

Strategic In-Licensing Expands Neurology Footprint

Axsome underscored its business development strategy with the in‑licensing of AZD7325, now AXS‑17, which has shown favorable safety in more than 700 patients to date. The company is planning Phase II‑enabling work with an initial focus on epilepsy, citing compelling preclinical seizure data and positioning AXS‑17 as a potential future growth driver in central nervous system disorders.

Profitability Trends Improve as Cash Buffer Holds

The company’s net loss narrowed meaningfully, with Q4 2025 net loss at $28.6 million versus $74.9 million a year earlier and full‑year net loss improving to $183.2 million from $287.2 million. Year‑end cash and equivalents stood at $323 million, slightly above the prior year, and management reiterated that this balance should be sufficient to carry Axsome to cash‑flow breakeven under its current operating plan.

Scaling Commercial Muscle for Future Launches

Axsome is aggressively expanding its commercial infrastructure, doubling its sales force toward roughly 600 representatives to support existing MDD growth and a potential Alzheimer’s agitation launch. A direct‑to‑consumer campaign has already driven an inflection in new patient starts for Auvelity, and the company plans further optimization of its promotional mix through 2026.

Margin Headwinds from Rising Gross-to-Net Discounts

Management cautioned that gross‑to‑net discounts remain a headwind, with Auvelity and Sunosi in the high‑40% range during 2025 and expected to rise to the mid‑50% area, particularly due to typical first‑quarter dynamics. Cymbravo’s gross‑to‑net was in the high‑70% range in Q4 and is expected to stay elevated through the launch phase, limiting near‑term net revenue despite growing prescription volumes.

SG&A Spending Climbs as Axsome Invests for Scale

Selling, general and administrative expenses increased 39% year over year to $570.6 million in 2025, up from $411.4 million in 2024, reflecting the cost of sales‑force expansion and heavy marketing, including DTC campaigns. Management framed this SG&A ramp as critical to building durable branded franchises, but investors will be watching how quickly revenue growth can outpace these escalating costs.

Ongoing Net Losses and Stock-Based Pay Weigh on Valuation

Despite progress, Axsome remains in the red with a $183.2 million full‑year net loss that includes $93.8 million in stock‑based compensation, a sizable non‑cash but investor‑relevant expense. The combination of continued operating losses and high equity compensation could remain an overhang until the company reaches sustained profitability and demonstrates tighter cost discipline.

Cymbravo Faces Access and Economics Challenges

Management acknowledged that Cymbravo’s contribution will likely stay limited in the near term, given modest sales, payer coverage of roughly 52%, and high gross‑to‑net discounts in the high‑70% range. The company is focused on access work and payer contracting to improve economics over time, but investors should expect a gradual build rather than a rapid revenue ramp from this asset.

Delay in Shift Work Disorder Extends Optionality

Axsome now expects top‑line data for solriamfetol in shift work disorder in 2027 due to slower‑than‑planned enrollment, pushing out a potential label expansion and associated revenue upside. While the delay does not change the company’s broader growth pillars, it removes a near‑term catalyst and pushes that particular opportunity further down the valuation timeline.

Alzheimer’s Agitation Opportunity and Payer Uncertainty

The proposed Auvelity indication in Alzheimer’s agitation could be heavily Medicare Part D‑weighted, with management expecting more than 70% of prescriptions from that channel if approved. While this mix might ultimately improve gross‑to‑net economics, the company emphasized that access and coverage are not guaranteed, and payer negotiations after approval will be crucial to realizing the indication’s full commercial potential.

Guidance Points to a Catalyst-Rich 2026

Looking ahead, the company expects a busy 2026, anchored by the Auvelity Alzheimer’s agitation review with a late‑April decision date and a fully ramped 600‑rep sales force by the second quarter. Multiple clinical events are on deck, including the AXS‑12 NDA filing for narcolepsy, Phase III initiation for AXS‑05 in smoking cessation, several solriamfetol Phase III trials across ADHD, MDD, and binge eating disorder, and continued advancement of AXS‑14 and AXS‑17, all supported by a cash balance expected to last through the move to cash‑flow positivity.

Axsome’s earnings call painted the picture of a company transitioning from high‑growth niche player to a broader CNS commercial platform, led by Auvelity’s blockbuster‑like trajectory. While high spending, discounts, and some trial delays raise execution risk, the strong top‑line growth, improving losses, and dense pipeline of near‑ and mid‑term catalysts keep the equity story very much in play for investors focused on growth in neuropsychiatric therapeutics.